Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Leukemia

  Free Subscription


Articles published in J Clin Oncol

Retrieve available abstracts of 88 articles:
HTML format



Single Articles


    June 2022
  1. ARMENIAN SH, Chen Y, Hageman L, Wu J, et al
    Burden of Long-Term Morbidity Borne by Survivors of Acute Myeloid Leukemia Treated With Blood or Marrow Transplantation: The Results of the BMT Survivor Study.
    J Clin Oncol. 2022 Jun 22:JCO2102829. doi: 10.1200/JCO.21.02829.
    PubMed     Abstract available


  2. MOORMAN AV, Antony G, Wade R, Butler ER, et al
    Time to Cure for Childhood and Young Adult Acute Lymphoblastic Leukemia Is Independent of Early Risk Factors: Long-Term Follow-Up of the UKALL2003 Trial.
    J Clin Oncol. 2022 Jun 17:JCO2200245. doi: 10.1200/JCO.22.00245.
    PubMed     Abstract available


  3. KADIA TM, Reville PK, Wang X, Rausch CR, et al
    Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia.
    J Clin Oncol. 2022 Jun 15:JCO2102823. doi: 10.1200/JCO.21.02823.
    PubMed     Abstract available


  4. HANTEL A, Kohlschmidt J, Eisfeld AK, Stock W, et al
    Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention.
    J Clin Oncol. 2022 Jun 13:JCO2200307. doi: 10.1200/JCO.22.00307.
    PubMed     Abstract available


  5. CHIHARA D, Huang EP, Finnigan SR, Cordes LM, et al
    Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute.
    J Clin Oncol. 2022;40:1949-1957.
    PubMed     Abstract available


    May 2022
  6. PASQUAL E, Schonfeld S, Morton LM, Villoing D, et al
    Association Between Radioactive Iodine Treatment for Pediatric and Young Adulthood Differentiated Thyroid Cancer and Risk of Second Primary Malignancies.
    J Clin Oncol. 2022;40:1439-1449.
    PubMed     Abstract available


    April 2022
  7. PERL AE
    Pediatric Acute Myeloid Leukemia Enters the Molecularly Targeted Era Via FLT3 Inhibition.
    J Clin Oncol. 2022 Apr 18:JCO2200499. doi: 10.1200/JCO.22.00499.
    PubMed    


  8. CHANG A, Akhtar A, Linderman SL, Lai L, et al
    Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.
    J Clin Oncol. 2022 Apr 18:JCO2200088. doi: 10.1200/JCO.22.00088.
    PubMed     Abstract available


  9. BLEAKLEY M, Sehgal A, Seropian S, Biernacki MA, et al
    Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease.
    J Clin Oncol. 2022;40:1174-1185.
    PubMed     Abstract available


  10. WALSH BS, Kesselheim AS, Sarpatwari A, Rome BN, et al
    Indication-Specific Generic Uptake of Imatinib Demonstrates the Impact of Skinny Labeling.
    J Clin Oncol. 2022;40:1102-1110.
    PubMed     Abstract available


    March 2022
  11. HOFSTE OP BRUININK D, Kuiper R, van Duin M, Cupedo T, et al
    Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile.
    J Clin Oncol. 2022 Mar 31:JCO2101217. doi: 10.1200/JCO.21.01217.
    PubMed     Abstract available


  12. POLLARD JA, Alonzo TA, Gerbing R, Brown P, et al
    Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031.
    J Clin Oncol. 2022 Mar 29:JCO2101612. doi: 10.1200/JCO.21.01612.
    PubMed     Abstract available


  13. MYERS RM, Taraseviciute A, Steinberg SM, Lamble AJ, et al
    Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL.
    J Clin Oncol. 2022;40:932-944.
    PubMed     Abstract available


  14. TEACHEY DT, Devidas M, Wood BL, Chen Z, et al
    Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.
    J Clin Oncol. 2022 Mar 10:JCO2102678. doi: 10.1200/JCO.21.02678.
    PubMed     Abstract available


    February 2022
  15. ADVANI AS, Moseley A, O'Dwyer KM, Wood BL, et al
    SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2022 Feb 14:JCO2101766. doi: 10.1200/JCO.21.01766.
    PubMed     Abstract available


    January 2022
  16. JORDHEIM LP
    Toward Personalization of Cytarabine Dosing in Acute Myeloid Leukemia.
    J Clin Oncol. 2022 Jan 13:JCO2102723. doi: 10.1200/JCO.21.02723.
    PubMed    


  17. O'BRIEN MM, Ji L, Shah NN, Rheingold SR, et al
    Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621.
    J Clin Oncol. 2022 Jan 10:JCO2101693. doi: 10.1200/JCO.21.01693.
    PubMed     Abstract available


  18. DINARDO CD, Pollyea DA
    Beyond Survival: The US Food and Drug Administration Confirms Surrogate End Points for Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Intensive Chemotherapy.
    J Clin Oncol. 2022 Jan 10:JCO2102762. doi: 10.1200/JCO.21.02762.
    PubMed    


  19. GIBSON CJ, Kim HT, Zhao L, Murdock HM, et al
    Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation.
    J Clin Oncol. 2022;40:189-201.
    PubMed     Abstract available


  20. ELSAYED AH, Cao X, Mitra AK, Wu H, et al
    Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation.
    J Clin Oncol. 2022 Jan 6:JCO2101422. doi: 10.1200/JCO.21.01422.
    PubMed     Abstract available


    December 2021
  21. PRATZ KW, Jonas BA, Pullarkat V, Recher C, et al
    Measurable Residual Disease Response and Prognosis in Treatment-Naive Acute Myeloid Leukemia With Venetoclax and Azacitidine.
    J Clin Oncol. 2021 Dec 15:JCO2101546. doi: 10.1200/JCO.21.01546.
    PubMed     Abstract available


  22. NORSWORTHY KJ, Gao X, Ko CW, Pulte ED, et al
    Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses.
    J Clin Oncol. 2021 Dec 10:JCO2101548. doi: 10.1200/JCO.21.01548.
    PubMed     Abstract available


  23. SCHULTZ LM, Baggott C, Prabhu S, Pacenta HL, et al
    Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report.
    J Clin Oncol. 2021 Dec 9:JCO2003585. doi: 10.1200/JCO.20.03585.
    PubMed     Abstract available


  24. LAMBLE AJ, Eidenschink Brodersen L, Alonzo TA, Wang J, et al
    CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group.
    J Clin Oncol. 2021 Dec 2:JCO2101595. doi: 10.1200/JCO.21.01595.
    PubMed     Abstract available


    October 2021
  25. NAKAMURA R, Saber W, Martens MJ, Ramirez A, et al
    Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome.
    J Clin Oncol. 2021;39:3328-3339.
    PubMed     Abstract available


  26. WIERDA WG, Allan JN, Siddiqi T, Kipps TJ, et al
    Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.
    J Clin Oncol. 2021 Oct 7:JCO2100807. doi: 10.1200/JCO.21.00807.
    PubMed     Abstract available


  27. POLLARD JA, Guest E, Alonzo TA, Gerbing RB, et al
    Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531.
    J Clin Oncol. 2021;39:3149-3160.
    PubMed     Abstract available


    August 2021
  28. RODDIE C, Dias J, O'Reilly MA, Abbasian M, et al
    Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2021 Aug 31:JCO2100917. doi: 10.1200/JCO.21.00917.
    PubMed     Abstract available


  29. ABDEL-QADIR H, Sabrie N, Leong D, Pang A, et al
    Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study.
    J Clin Oncol. 2021 Aug 31:JCO2100693. doi: 10.1200/JCO.21.00693.
    PubMed     Abstract available


  30. SHORT NJ, Kantarjian H
    When Less Is More: Reevaluating the Role of Intensive Chemotherapy for Older Adults With Acute Myeloid Leukemia in the Modern Era.
    J Clin Oncol. 2021 Aug 18:JCO2100960. doi: 10.1200/JCO.21.00960.
    PubMed    


    July 2021
  31. PAN J, Tan Y, Wang G, Deng B, et al
    Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial.
    J Clin Oncol. 2021 Jul 29:JCO2100389. doi: 10.1200/JCO.21.00389.
    PubMed     Abstract available


  32. STEPHENS DM
    Second-Generation Bruton's Tyrosine Kinase Inhibitors: Simply the Best Treatments for Chronic Lymphocytic Leukemia?
    J Clin Oncol. 2021 Jul 26:JCO2101414. doi: 10.1200/JCO.21.01414.
    PubMed    


  33. BYRD JC, Hillmen P, Ghia P, Kater AP, et al
    Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.
    J Clin Oncol. 2021 Jul 26:JCO2101210. doi: 10.1200/JCO.21.01210.
    PubMed     Abstract available


  34. GUI G, Dillon LW, Hourigan CS
    Measurable Residual Disease Before Reduced-Intensity Allogeneic Transplantation in Patients With Myeloid Malignancy.
    J Clin Oncol. 2021;39:2413-2415.
    PubMed    


  35. VROOMAN LM, Blonquist TM, Stevenson KE, Supko JG, et al
    Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001.
    J Clin Oncol. 2021 Jul 6:JCO2003692. doi: 10.1200/JCO.20.03692.
    PubMed     Abstract available


    June 2021
  36. DESAI PM, Brown J, Gill S, Solh MM, et al
    Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia.
    J Clin Oncol. 2021 Jun 22:JCO2001739. doi: 10.1200/JCO.20.01739.
    PubMed     Abstract available


  37. MYERS RM, Li Y, Barz Leahy A, Barrett DM, et al
    Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2021 Jun 22:JCO2003458. doi: 10.1200/JCO.20.03458.
    PubMed     Abstract available


  38. WEI AH, Roboz GJ, Kantarjian HM
    Harnessing the Therapeutic Value of Venetoclax: A Breakthrough Therapy in Acute Myeloid Leukemia.
    J Clin Oncol. 2021 Jun 4:JCO2100080. doi: 10.1200/JCO.21.00080.
    PubMed    


  39. ZHENG H, Jiang H, Hu S, Liao N, et al
    Arsenic Combined With All-Trans Retinoic Acid for Pediatric Acute Promyelocytic Leukemia: Report From the CCLG-APL2016 Protocol Study.
    J Clin Oncol. 2021 Jun 2:JCO2003096. doi: 10.1200/JCO.20.03096.
    PubMed     Abstract available


    May 2021
  40. SHORT NJ, Tallman MS, Pollyea DA, Ravandi F, et al
    Optimizing Risk Stratification in Acute Myeloid Leukemia: Dynamic Models for a Dynamic Therapeutic Landscape.
    J Clin Oncol. 2021 May 27:JCO2100067. doi: 10.1200/JCO.21.00067.
    PubMed    


  41. DINARDO CD, Lachowiez CA, Takahashi K, Loghavi S, et al
    Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.
    J Clin Oncol. 2021 May 27:JCO2003736. doi: 10.1200/JCO.20.03736.
    PubMed     Abstract available


  42. SHAH NN, Lee DW, Yates B, Yuan CM, et al
    Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL.
    J Clin Oncol. 2021;39:1650-1659.
    PubMed     Abstract available


    April 2021
  43. SHAW BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, et al
    National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide.
    J Clin Oncol. 2021 Apr 27:JCO2003502. doi: 10.1200/JCO.20.03502.
    PubMed     Abstract available


  44. VAN DER PLAS E, Modi AJ, Li CK, Krull KR, et al
    Cognitive Impairment in Survivors of Pediatric Acute Lymphoblastic Leukemia Treated With Chemotherapy Only.
    J Clin Oncol. 2021 Apr 22:JCO2002322. doi: 10.1200/JCO.20.02322.
    PubMed    


    March 2021
  45. MATTANO LA JR, Devidas M, Maloney KW, Wang C, et al
    Favorable Trisomies and ETV6-RUNX1 Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331.
    J Clin Oncol. 2021 Mar 19:JCO2002370. doi: 10.1200/JCO.20.02370.
    PubMed     Abstract available


    February 2021
  46. CLUZEAU T, Sebert M, Rahme R, Cuzzubbo S, et al
    Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myelodysplasies (GFM).
    J Clin Oncol. 2021 Feb 18:JCO2002342. doi: 10.1200/JCO.20.02342.
    PubMed     Abstract available


  47. RIMANDO JC, Christopher MJ, Rettig MP, DiPersio JF, et al
    Biology of Disease Relapse in Myeloid Disease: Implication for Strategies to Prevent and Treat Disease Relapse After Stem-Cell Transplantation.
    J Clin Oncol. 2021;39:386-396.
    PubMed    


  48. PETERS C, Dalle JH, Locatelli F, Poetschger U, et al
    Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study.
    J Clin Oncol. 2021;39:295-307.
    PubMed     Abstract available


    January 2021
  49. AGRAWAL AK, Michlitsch J, Golden C, Hastings CA, et al
    Nelarabine in Pediatric and Young Adult T-Cell Acute Lymphoblastic Leukemia-Clearly Beneficial?
    J Clin Oncol. 2021 Jan 14:JCO2002973. doi: 10.1200/JCO.20.02973.
    PubMed    


  50. LUSSANA F, Gritti G, Rambaldi A
    Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell-Redirected Bispecific Antibodies.
    J Clin Oncol. 2021 Jan 12:JCO2001564. doi: 10.1200/JCO.20.01564.
    PubMed    


  51. O'NEILL AT, Chakraverty R
    Graft Versus Leukemia: Current Status and Future Perspectives.
    J Clin Oncol. 2021 Jan 12:JCO2001801. doi: 10.1200/JCO.20.01801.
    PubMed     Abstract available


  52. KHALDOYANIDI S, Nagorsen D, Stein A, Ossenkoppele G, et al
    Immune Biology of Acute Myeloid Leukemia: Implications for Immunotherapy.
    J Clin Oncol. 2021 Jan 12:JCO2000475. doi: 10.1200/JCO.20.00475.
    PubMed    


  53. KADAUKE S, Myers RM, Li Y, Aplenc R, et al
    Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial.
    J Clin Oncol. 2021 Jan 8:JCO2002477. doi: 10.1200/JCO.20.02477.
    PubMed     Abstract available


  54. LUGER SM
    Consolidation Therapy for Acute Myeloid Leukemia: Defining a Benchmark.
    J Clin Oncol. 2021 Jan 7:JCO2003142. doi: 10.1200/JCO.20.03142.
    PubMed     Abstract available


  55. ANGIOLILLO AL, Schore RJ, Kairalla JA, Devidas M, et al
    Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932.
    J Clin Oncol. 2021 Jan 7:JCO2000494. doi: 10.1200/JCO.20.00494.
    PubMed     Abstract available


  56. STUTTERHEIM J, van der Sluis IM, de Lorenzo P, Alten J, et al
    Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol.
    J Clin Oncol. 2021 Jan 6:JCO2002333. doi: 10.1200/JCO.20.02333.
    PubMed     Abstract available


    December 2020
  57. CRADDOCK C, Jackson A, Loke J, Siddique S, et al
    Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia.
    J Clin Oncol. 2020 Dec 29:JCO2002308. doi: 10.1200/JCO.20.02308.
    PubMed     Abstract available


  58. BURNETT AK, Russell NH, Hills RK, Knapper S, et al
    Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses.
    J Clin Oncol. 2020 Dec 23:JCO2001170. doi: 10.1200/JCO.20.01170.
    PubMed     Abstract available


  59. GAO L, Zhang Y, Wang S, Kong P, et al
    Effect of rhG-CSF Combined With Decitabine Prophylaxis on Relapse of Patients With High-Risk MRD-Negative AML After HSCT: An Open-Label, Multicenter, Randomized Controlled Trial.
    J Clin Oncol. 2020;38:4249-4259.
    PubMed     Abstract available


  60. PALMIERI R, Othus M, Halpern AB, Percival MM, et al
    Accuracy of SIE/SIES/GITMO Consensus Criteria for Unfitness to Predict Early Mortality After Intensive Chemotherapy in Adults With AML or Other High-Grade Myeloid Neoplasm.
    J Clin Oncol. 2020;38:4163-4174.
    PubMed     Abstract available


    October 2020
  61. DINARDO CD, Stein AS, Stein EM, Fathi AT, et al
    Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia.
    J Clin Oncol. 2020 Oct 29:JCO2001632. doi: 10.1200/JCO.20.01632.
    PubMed     Abstract available


  62. SALAMERO O, Montesinos P, Willekens C, Perez-Simon JA, et al
    First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia.
    J Clin Oncol. 2020 Oct 14:JCO1903250. doi: 10.1200/JCO.19.03250.
    PubMed     Abstract available


  63. STILGENBAUER S
    Four-Factor Score for Outcome of Ibrutinib Treatment in Chronic Lymphocytic Leukemia: Prognostic Model for Risk Group Definition.
    J Clin Oncol. 2020 Oct 13:JCO2002685. doi: 10.1200/JCO.20.02685.
    PubMed    


  64. AHN IE, Tian X, Ipe D, Cheng M, et al
    Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model.
    J Clin Oncol. 2020 Oct 7:JCO2000979. doi: 10.1200/JCO.20.00979.
    PubMed     Abstract available


    September 2020
  65. KATER AP, Wu JQ, Kipps T, Eichhorst B, et al
    Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study.
    J Clin Oncol. 2020 Sep 28:JCO2000948. doi: 10.1200/JCO.20.00948.
    PubMed     Abstract available


  66. LEHRNBECHER T, Fisher BT, Phillips B, Beauchemin M, et al
    Clinical Practice Guideline for Systemic Antifungal Prophylaxis in Pediatric Patients With Cancer and Hematopoietic Stem-Cell Transplantation Recipients.
    J Clin Oncol. 2020;38:3205-3216.
    PubMed     Abstract available


  67. STEPHENS DM, Byrd JC
    Next-Generation Bruton Tyrosine Kinase Inhibitors.
    J Clin Oncol. 2020;38:2937-2940.
    PubMed    


    August 2020
  68. DUNSMORE KP, Winter SS, Devidas M, Wood BL, et al
    Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2020 Aug 19:JCO2000256. doi: 10.1200/JCO.20.00256.
    PubMed     Abstract available


  69. ROGERS KA, Huang Y, Ruppert AS, Abruzzo LV, et al
    Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naive and Relapsed or Refractory Chronic Lymphocytic Leukemia.
    J Clin Oncol. 2020 Aug 14:JCO2000491. doi: 10.1200/JCO.20.00491.
    PubMed     Abstract available


  70. MELCHIONE C
    Journal Honors Rahul S. Vedula, MD, As Recipient of the 2020 Journal of Clinical Oncology Young Investigator Award.
    J Clin Oncol. 2020;38:2601-2602.
    PubMed    


    July 2020
  71. OSSENKOPPELE G, Vyas P
    BCL-2 Inhibitor and Conventional Chemotherapy Combinations for Acute Myeloid Leukemia: Shifting From the Unfit to the Fit Patient With AML.
    J Clin Oncol. 2020 Jul 30:JCO2001788. doi: 10.1200/JCO.20.01788.
    PubMed    


  72. EASTHAM JA, Heller G, Halabi S, Monk JP 3rd, et al
    Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer.
    J Clin Oncol. 2020 Jul 24:JCO2000315. doi: 10.1200/JCO.20.00315.
    PubMed     Abstract available


  73. KROGER N
    Preventing Graft-Versus-Host Disease Without Losing Graft-Versus-Leukemia Effect After Allogeneic Stem-Cell Transplantation.
    J Clin Oncol. 2020 Jul 24:JCO2001756. doi: 10.1200/JCO.20.01756.
    PubMed    


  74. DIXON SB, Chen Y, Yasui Y, Pui CH, et al
    Reduced Morbidity and Mortality in Survivors of Childhood Acute Lymphoblastic Leukemia: A Report From the Childhood Cancer Survivor Study.
    J Clin Oncol. 2020 Jul 24:JCO2000493. doi: 10.1200/JCO.20.00493.
    PubMed     Abstract available


  75. CHUA CC, Roberts AW, Reynolds J, Fong CY, et al
    Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy.
    J Clin Oncol. 2020 Jul 20:JCO2000572. doi: 10.1200/JCO.20.00572.
    PubMed     Abstract available


  76. BURCHERT A, Bug G, Fritz LV, Finke J, et al
    Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN).
    J Clin Oncol. 2020 Jul 16:JCO1903345. doi: 10.1200/JCO.19.03345.
    PubMed     Abstract available


    June 2020
  77. HAYASHI RJ, Winter SS, Dunsmore KP, Devidas M, et al
    Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434.
    J Clin Oncol. 2020 Jun 17:JCO2000531. doi: 10.1200/JCO.20.00531.
    PubMed     Abstract available


  78. SHAH NN, Highfill SL, Shalabi H, Yates B, et al
    CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial.
    J Clin Oncol. 2020;38:1938-1950.
    PubMed     Abstract available


  79. SALZER WL, Burke MJ, Devidas M, Dai Y, et al
    Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children's Oncology Group Study AALL1131.
    J Clin Oncol. 2020 Jun 4:JCO1902892. doi: 10.1200/JCO.19.02892.
    PubMed     Abstract available


    May 2020
  80. GHIA P, Pluta A, Wach M, Lysak D, et al
    ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
    J Clin Oncol. 2020 May 27:JCO1903355. doi: 10.1200/JCO.19.03355.
    PubMed     Abstract available


  81. COOPER TM, Absalon MJ, Alonzo TA, Gerbing RB, et al
    Phase I/II Study of CPX-351 Followed by Fludarabine, Cytarabine, and Granulocyte-Colony Stimulating Factor for Children With Relapsed Acute Myeloid Leukemia: A Report From the Children's Oncology Group.
    J Clin Oncol. 2020 May 13:JCO1903306. doi: 10.1200/JCO.19.03306.
    PubMed     Abstract available


    April 2020
  82. GETZ KD, Sung L, Alonzo TA, Leger KJ, et al
    Effect of Dexrazoxane on Left Ventricular Systolic Function and Treatment Outcomes in Patients With Acute Myeloid Leukemia: A Report From the Children's Oncology Group.
    J Clin Oncol. 2020 Apr 28:JCO1902856. doi: 10.1200/JCO.19.02856.
    PubMed     Abstract available


  83. LADAS EJ, Blonquist TM, Puligandla M, Orjuela M, et al
    Protective Effects of Dietary Intake of Antioxidants and Treatment-Related Toxicity in Childhood Leukemia: A Report From the DALLT Cohort.
    J Clin Oncol. 2020 Apr 24:JCO1902555. doi: 10.1200/JCO.19.02555.
    PubMed     Abstract available


  84. FREY NV, Gill S, Hexner EO, Schuster S, et al
    Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia.
    J Clin Oncol. 2020 Apr 16:JCO1903237. doi: 10.1200/JCO.19.03237.
    PubMed     Abstract available


  85. GUPTA S, Wang C, Raetz EA, Schore R, et al
    Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group.
    J Clin Oncol. 2020 Apr 10:JCO1903024. doi: 10.1200/JCO.19.03024.
    PubMed     Abstract available


    March 2020
  86. PYZER AR
    Pigeon English.
    J Clin Oncol. 2020;38:841-842.
    PubMed    


    February 2020
  87. WHITTINGTON MD, McQueen RB, Campbell JD
    Valuing Chimeric Antigen Receptor T-Cell Therapy: Current Evidence, Uncertainties, and Payment Implications.
    J Clin Oncol. 2020;38:359-366.
    PubMed    


    May 2019
  88. GRAFF SL
    The Cattle Don't Care.
    J Clin Oncol. 2019;37:1136-1138.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: